Список литературы

1. Кохно А.В. et al. Миелодиспластические синдромы и апластическая анемия // Программное лечение заболеваний крови, под ред. Савченко В.Г. 2012. P. 83 - 150.

2. Ширин А.Д., Френкель М.А. Миелодиспластические синдромы // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд., перераб. и доп. 2007. P. 502 - 551.

3. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. // Am. J. Hematol. 2015. Vol. 90, N 9. P. 831 - 841.

4. Malcovati L. et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. // Blood. 2013. Vol. 122, N 17. P. 2943 - 2964.

5. Greenberg P.L. et al. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. 2019.

6. Goldberg S.L. et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. // J. Clin. Oncol. 2010. Vol. 28, N 17. P. 2847 - 2852.

7. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, 2008. 439 p.

8. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.

9. Valent P. et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions // Oncotarget. Impact Journals, LLC, 2017. Vol. 8, N 43.

10. Gregg X.T., Reddy V., Prchal J.T. Copper deficiency masquerading as myelodysplastic syndrome. // Blood. 2002. Vol. 100, N 4. P. 1493 - 1495.

11. Irving J.A. et al. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. // CMAJ. 2003. Vol. 169, N 2. P. 129 - 131.

12. Amin H.M. et al. Having a higher blast percentage in circulation than bone marrow: Clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias // Leukemia. Nature Publishing Group, 2005. Vol. 19, N 9. P. 1567 - 1572.

13. E. et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. // Br. J. Haematol. 1997. Vol. 99, N 2. P. 344 - 351.

14. Seguier J. et al. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. // Autoimmun. Rev. 2019. Vol. 18, N 1. P. 36 - 42.

15. Wang H. et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome // Blood. 2002. Vol. 100, N 12. P. 3897 - 3902.

16. Yoshida Y. et al. Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. // Int. J. Hematol. 2014. Vol. 99, N 6. P. 721 - 725.

17. Mufti G.J. et al. Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES // Br. J. Haematol. 1986. Vol. 63, N 1. P. 143 - 147.

18. De Hollanda A. et al. Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study // Arthritis Care Res. 2011. Vol. 63, N 8. P. 1188 - 1194.

19. Wolach O., Stone R. Autoimmunity and Inflammation in Myelodysplastic Syndromes // Acta Haematol. 2016. Vol. 136, N 2. P. 108 - 117.

20. Yarali N. et al. Parvovirus B19 infection reminiscent of myelodysplastic syndrome in three children with chronic hemolytic anemia // Pediatr. Hematol. Oncol. Taylor and Francis Inc., 2000. Vol. 17, N 6. P. 475 - 482.

21. Wajcman H., Moradkhani K. Abnormal haemoglobins: Detection & characterization // Indian Journal of Medical Research. 2011. Vol. 134, N 10. P. 538 - 546.

22. Fong T. et al. Copper deficiency: An important consideration in the differential diagnosis of myelodysplastic syndrome // Haematologica. 2007. Vol. 92, N 10. P. 1429 - 1430.

23. Thakral B., Saluja K., Eldibany M. Zinc-induced copper deficiency: a diagnostic pitfall of myelodysplastic syndrome. // Pathology. 2014. Vol. 46, N 3. P. 246 - 248.

24. Dorgalaleh A. et al. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. // Iran. J. Pediatr. Hematol. Oncol. 2013. Vol. 3, N 2. P. 73 - 77.

25. Bennett J.M., Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: Recommendations for a standardized approach // Haematologica. 2009. Vol. 94, N 2. P. 264 - 268.

26. Goasguen J.E. et al. Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia. // Leuk. Res. 2016. Vol. 45. P. 75 - 81.

27. Mufti G.J. et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. // Haematologica. 2008. Vol. 93, N 11. P. 1712 - 1717.

28. Patnaik M.M., Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. // Am. J. Hematol. 2015. Vol. 90. N 6. P. 549 - 559.

29. Della Porta M.G. et al. Mitochondrial Ferritin Expression and Clonality of Hematopoiesis in Patients with Refractory Anemia with Ringed Sideroblasts. // Blood. 2005. Vol. 106, N 11. P. 3444.

30. Greenberg P.L. et al. Revised international prognostic scoring system for myelodysplastic syndromes // Blood. 2012. Vol. 120, N 12. P. 2454 - 2465.

31. Gupta R. et al. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. // Br. J. Haematol. 2007. Vol. 139, N 2. P. 265 - 268.

32. Gyan E., Dreyfus F., Fenaux P. Refractory thrombocytopenia and neutropenia: a diagnostic challenge. // Mediterr. J. Hematol. Infect. Dis. 2015. Vol. 7, N 1. P. e2015018.

33. Mallo M. et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. // Leukemia. 2011. Vol. 25, N 1. P. 110 - 120.

34. Olney H.J., Le Beau M.M. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. // Leuk. Res. 2007. Vol. 31, N 4. P. 427 - 434.

35. Rogers H.J. et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. // Haematologica. 2014. Vol. 99, N 5. P. 821 - 829.

36. Schanz J. et al. New comprehensive cytogenetic scoring system for MDS and oligoblastic AML after MDS // J. Clin. Oncol. 2012. Vol. 30, N 8. P. 820 - 829.

37. Steensma D.P. et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? // Leuk. Res. 2003. Vol. 27, N 3. P. 235 - 242.

38. Paulsson K., Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. // Pathol. Biol. (Paris). 2007. Vol. 55, N 1. P. 37 - 48.

39. Bigoni R. et al. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. // Haematologica. 2001. Vol. 86, N 4. P. 375 - 381.

40. Fu B. et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. // Mod. Pathol. 2014. Vol. 27, N 5. P. 681 - 689.

41. Huang T.C. et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies // Leukemia. Nature Publishing Group, 2008. Vol. 22, N 3. P. 544 - 550.

42. Maschek H. et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. // Eur. J. Haematol. 1992. Vol. 48, N 4. P. 208 - 214.

43. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases // Pathobiology. 2007. Vol. 74, N 2. P. 97 - 114.

44. Yue G. et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. // Leuk. Res. 2008. Vol. 32, N 4. P. 553 - 558.

45. Della Porta M.G. et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. // J. Clin. Oncol. 2009. Vol. 27, N 5. P. 754 - 762.

46. Orazi A. et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. // Am. J. Clin. Pathol. 1997. Vol. 107, N 3. P. 268 - 274.

47. Verburgh E. et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. // J. Clin. Oncol. 2003. Vol. 21, N 2. P. 273 - 282.

48. Alhan C. et al. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. // Br. J. Haematol. 2014. Vol. 167, N 1. P. 100 - 109.

49. Alhan C. et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes // Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2014. Vol. 86, N 3. P. 207 - 215.

50. Bardet V. et al. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. // Haematologica. 2015. Vol. 100, N 4. P. 472 - 478.

51. Porta M.G.D. et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: Results of a European LeukemiaNET study // Haematologica. 2012. Vol. 97, N 8. P. 1209 - 1217.

52. Della Porta M.G. et al. Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. // Haematologica. 2014. Vol. 99, N 1. P. e8 - 10.

53. Kern W. et al. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. // Cancer. 2010. Vol. 116, N 19. P. 4549 - 4563.

54. Haferlach T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes // Leukemia. 2014. Vol. 28, N 2. P. 241 - 247.

55. Malcovati L. et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts // Blood. American Society of Hematology, 2015. Vol. 126, N 2. P. 233 - 241.

56. Mallo M. et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. // Br. J. Haematol. 2013. Vol. 162, N 1. P. 74 - 86.

57. Ingram W. et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. // Leukemia. 2006. Vol. 20, N 7. P. 1319 - 1321.

58. Malcovati L., Rumi E., Cazzola M. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms // Haematologica. Ferrata Storti Foundation, 2014. Vol. 99, N 11. P. 1650 - 1652.

59. Savage S.A., Walsh M.F. Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia // Hematology/Oncology Clinics of North America. W.B. Saunders, 2018. Vol. 32, N 4. P. 657 - 668.

60. Della Porta M.G. et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). // Blood. 2014. P. 2333 - 2342.

61. Аксельрод Б.А. et al. Клиническое использование эритроцитсодержащих компонентов донорской крови // Гематология и трансфузиология. 2018. Vol. 63, N 4. P. 372 - 435.

62. Bruzzone M.G. et al. CT and MRI of brain tumors // Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2012. Vol. 56, N 2. P. 112 - 137.

63. Greenberg P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. // Blood. 1997. Vol. 89, N 6. P. 2079 - 2088.

64. Malcovati L. et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). // Haematologica. 2011. Vol. 96, N 10. P. 1433 - 1440.

65. Cheson B.D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. // Blood. 2006. Vol. 108, N 2. P. 419 - 425.

66. Hoeks M.P.A. et al. Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis. // Br. J. Haematol. 2017. Vol. 178, N 1. P. 137 - 151.

67. Rose C. et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des ). // Leuk. Res. 2010. Vol. 34, N 7. P. 864 - 870.

68. Neukirchen J. et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the MDS registry. // Leuk. Res. 2012. Vol. 36, N 8. P. 1067 - 1070.

69. Neukirchen J. et al. The impact of iron chelation therapy on clinical outcomes in realworld lower-risk patients with myelodysplastic syndromes (MDS): results from the Dusseldorf registry. // Haematologica. 2012. Vol. 97, N Supp.1. P. Abstract 144.

70. Komrokji R.S. et al. Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moftt Cancer Center. // Blood. 2011. Vol. 118. P. Abstract 2776.

71. Zeidan A.M. et al. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes // J. Comp. Eff. Res. Future Medicine Ltd., 2015. Vol. 4, N 4. P. 327 - 340.

72. Delforge M. et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. // Leuk. Res. 2014. Vol. 38, N 5. P. 557 - 563.

73. Lyons R.M. et al. Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months // Blood (ASH Annu. Meet. Abstr. 2012. Vol. 120, N 21. P. Abstract 1350.

74. Remacha et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. // Ann. Hematol. 2015. Vol. 94, N 5. P. 779 - 787.

75. Park S. et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. // Br. J. Haematol. 2019. Vol. 184, N 2. P. 134 - 160.

76. Platzbecker U. et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes // Leukemia. Nature Publishing Group, 2017. Vol. 31, N 9. P. 1944 - 1950.

77. Park S. et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis // Br. J. Haematol. Blackwell Publishing Ltd, 2016. Vol. 174, N 5. P. 730 - 747.

78. E. et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. // Blood. 1998. Vol. 92, N 1. P. 68 - 75.

79. M. et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome // J. Clin. Oncol. 2008. Vol. 26, N 21. P. 3607 - 3613.

80. Park S. et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience // Blood. American Society of Hematology, 2008. Vol. 111, N 2. P. 574 - 582.

81. Greenberg P.L. et al. A randomized controlled trial of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving decitabine. // Leuk. Lymphoma. 2013. Vol. 54, N 2. P. 321 - 328.

82. Kantarjian H. et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. // J. Clin. Oncol. 2010. Vol. 28, N 3. P. 437 - 444.

83. Kantarjian H.M. et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. // Blood. 2010. Vol. 116, N 17. P. 3163 - 3170.

84. Sekeres M.A. et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. // Cancer. 2011. Vol. 117, N 5. P. 992 - 1000.

85. Giagounidis A. et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. // Cancer. 2014. Vol. 120, N 12. P. 1838 - 1846.

86. Oliva E.N. et al. Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial // Blood. 2015. Vol. 126, N 23.

87. Oliva E.N. et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. // Lancet. Haematol. 2017. Vol. 4, N 3. P. e127 - e136.

88. Khan M. et al. Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial // Blood. 2015. Vol. 126, N 23.

89. Mittelman M. et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. // Lancet. Haematol. 2018. Vol. 5, N 1. P. e34 - e43.

90. Stahl M. et al. Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. // Haematologica. 2019.

91. List A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. // N. Engl. J. Med. 2006. Vol. 355, N 14. P. 1456 - 1465.

92. Fenaux P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study // Lancet Oncol. 2009. Vol. 10, N 3. P. 223 - 232.

93. Kantarjlan H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study // Cancer. 2006. Vol. 106, N 8. P. 1794 - 1803.

94. Silverman L.R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B // J. Clin. Oncol. 2002. Vol. 20, N 10. P. 2429 - 2440.

95. Kantarjian H. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia // Blood. 2007. Vol. 109, N 1. P. 52 - 57.

96. Pan T. et al. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies // Leuk. Res. Elsevier Ltd, 2018. Vol. 71. P. 13 - 24.

97. Ye L. et al. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone // J. Cancer Res. Clin. Oncol. Springer Verlag, 2017. Vol. 143, N 5. P. 873 - 882.

98. Ye X.-N. et al. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. // Leuk. Lymphoma. 2016. Vol. 57, N 6. P. 1311 - 1318.

99. Кохно А.В., Паровичникова Е.Н., Савченко В.Г. Протокол сочетанного применения гипометилирующих препаратов с низкодозной полихимиотерапией у больных МДС из группы высокого риска, ОМЛ из МДС, МДС/ОМЛ после апластической анемии, МДС/ОМЛ после лучевой и цитостатической терапии по поводу другого заболеван // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. НМИЦ Гематологии. Под ред. В.Г. Савченко. 2018. P. 829 - 840.

100. Visani G. et al. Low dose Ara-C for myelodysplastic syndromes: Is it still a current therapy? // Leukemia and Lymphoma. 2004. Vol. 45, N 8. P. 1531 - 1538.

101. Estey E.H. et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. // Blood. 2001. Vol. 98, N 13. P. 3575 - 3583.

102. Robak T. et al. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. // Neoplasma. 2003. Vol. 50, N 3. P. 172 - 175.

103. Omoto E. et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. // Leukemia. 1996. Vol. 10, N 4. P. 609 - 614.

104. Oliansky D.M. et al. The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review // Biology of Blood and Marrow Transplantation. Elsevier Inc., 2009. Vol. 15, N 2. P. 137 - 172.

105. Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. // Blood. 2005. Vol. 106, N 8. P. 2912 - 2919.

106. Hilarius D.L. et al. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. // Support. Care Cancer. 2012. Vol. 20, N 1. P. 107 - 117.

107. Belay Y., Yirdaw K., Enawgaw B. Tumor Lysis Syndrome in Patients with Hematological Malignancies // Journal of Oncology. Hindawi Limited, 2017. Vol. 2017.

108. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011) // Haematologica. 2013. Vol. 98, N 12. P. 1836 - 1847.

109. Heinz W.J. et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) // Annals of Hematology. Springer Verlag, 2017. Vol. 96, N 11. P. 1775 - 1792.

110. Loth K. et al. Infectious Complications Associated with the Use of Antithymocyte Globulin in Reduced Intensity Allogeneic Transplants // Antithymocyte Globul. Reduc. Intensity Allogeneic Transplants. Chemother. 2012. Vol. 2012, N 4. P. 106.

111. Alkharabsheh O.A. et al. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. // Ann. Hematol. 2019. Vol. 98, N 2. P. 331 - 337.

112. Stanworth S.J. et al. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management. // Br. J. Haematol. 2015. Vol. 171, N 3. P. 297 - 305.

113. Weisdorf S.A. et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. // Transplantation. 1987. Vol. 43, N 6. P. 833 - 838.

114. Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, N 1. P. 11 - 48.

115. Bennardello F. et al. The prevention of adverse reactions to transfusions in patients with haemoglobinopathies: A proposed algorithm // Blood Transfus. 2013. Vol. 11, N 3. P. 377 - 384.

116. Bourgeois E. et al. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. // Leukemia. 2001. Vol. 15, N 6. P. 950 - 953.

117. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

118. European Physical and Rehabilitation Medicine Bodies Alliance. White book on physical and rehabilitation medicine in Europe (3th Edition): Chaper 1: Definition an conceps of PRM // Eur. J. Phys. Rehabil. Med. 2018. Vol. 54, N 2. P. 156 - 165.

119. Porta M. Della et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome // Haematologica. 2011. Vol. 96, N 3. P. 441 - 449.